Crona N, Silfverstolpe G, Enk L, Samsioe G
Maturitas. 1984 Dec;6(4):335-9. doi: 10.1016/0378-5122(84)90005-7.
Org OD 14 is a synthetic steroid which in animal bioassays displays oestrogenic as well as very weak androgenic-anabolic properties. Earlier studies have shown that it alleviates oestrogen-deficiency symptoms and retards osteoporosis. OD 14 can be administered continuously with little effect on the endometrium. The aim of this study was to evaluate the effect of OD 14 on apolipoprotein A1 (Apo-A1), the major protein constituent of the high-density lipoprotein (HDL) fraction, as compared with that of oestradiol valerate (E2V) and a placebo. Twenty-two women, who had been oophorectomized when undergoing surgical treatment for stage IB or IIA cervical carcinoma, were given OD 14 2.5 mg/day, a placebo, and E2V 2 mg/day for a period of 6 wk in each case using a double-blind, cross-over method. Serum Apo-A1 was determined by electro-immunoassay after each treatment period. There was a marked decrease in Apo-A1 after OD 14 as compared with the levels seen after the placebo and E2V. This decrease is interpreted as evidence of a strong androgenic influence by OD 14. In epidemiological studies low levels of Apo-A1 have been associated with a higher incidence of atherosclerosis and cardiovascular disease. Long-term treatment with OD 14 might therefore be hazardous in this respect.
Org OD 14是一种合成类固醇，在动物生物测定中显示出雌激素以及非常微弱的雄激素-同化特性。早期研究表明，它能缓解雌激素缺乏症状并延缓骨质疏松。OD 14可以连续给药，对子宫内膜影响很小。本研究的目的是评估OD 14与戊酸雌二醇（E2V）和安慰剂相比，对载脂蛋白A1（Apo-A1）的影响，Apo-A1是高密度脂蛋白（HDL）组分的主要蛋白质成分。22名因IB期或IIA期宫颈癌接受手术治疗时已行卵巢切除术的女性，采用双盲交叉法，分别给予OD 14 2.5毫克/天、安慰剂和E2V 2毫克/天，各为期6周。每个治疗期后通过电免疫测定法测定血清Apo-A1。与安慰剂和E2V治疗后的水平相比，OD 14治疗后Apo-A1明显下降。这种下降被解释为OD 14具有强烈雄激素影响的证据。在流行病学研究中，低水平的Apo-A1与动脉粥样硬化和心血管疾病的较高发病率相关。因此，从这方面来看，长期使用OD 14可能具有危险性。
